Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus

Area of Science:

• Oncolytic virotherapy
• Cancer genetics
• Prostate cancer research

Background:

• Advanced prostate cancer often exhibits genetic alterations (e.g., p53, Rb/E2F/p16) leading to resistance to hormonal therapies.
• Oncolytic adenovirus, engineered to target cancer-specific genetic defects, is an emerging therapeutic strategy.
• Virotherapy offers a novel approach to combat treatment-refractory prostate cancer.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a double-mutated adenovirus, AxdAdB-3 (E1A mutation, E1B 55KD deletion), against prostate cancer.
• To assess the oncolytic potential and safety profile of AxdAdB-3 in preclinical models.

Main Methods:

• Cytopathic effects of AxdAdB-3 were assessed in human prostate cancer cell lines (DU145, PC3, LNCaP) and normal prostate cells (PrEC, PrSC) using crystal violet staining and MTT assays.
• Therapeutic efficacy was evaluated in an orthotopic prostate cancer mouse model (DU145 xenograft in SCID mice).

Main Results:

• AxdAdB-3 demonstrated significant cytopathic effects against prostate cancer cell lines.
• No cytotoxicity was observed in normal prostate-derived cell lines, indicating selectivity.
• In vivo studies showed a notable antitumor effect and significantly improved survival in the orthotopic mouse model.

Conclusions:

• AxdAdB-3 exhibits potent oncolytic activity against prostate cancer cells with a favorable safety profile.
• This engineered adenovirus represents a promising candidate for virotherapy in patients with hormone-refractory prostate cancer.